Fiber and Systemic Inflammation

Over three grams of fiber

Over three grams of fiber

High dietary fiber intake helps prevent constipation, diverticular disease, hemorrhoids, irritable bowel syndrome, and perhaps colon polyps.  Soluble fiber helps control blood sugar levels in people with diabetes, and it reduces LDL cholesterol levels, thereby reducing risks of coronary heart disease.

An  article in the journal Nutrition suggests how fiber may have beneficial effects in atherosclerosis (the cause of heart attacks and strokes), type 2 diabetes, and some cancers.  These conditions are felt to be related to underlying systemic inflammation.

Systemic inflammation can be judged by blood levels of inflammatory markers such as interleukin-6, tumor necrosis factor-alpha-receptor-2, and high-sensitivity C-reactive protein.

Researchers looked at 1,958 postmenopausal women in the Women’s Health Initiative Observational Study, comparing inflammatory marker levels with dietary fiber intake.  They found that high fiber intake was associated with significantly lower levels of inflammatory markers interleukin-6 and tumor necrosis factor-alpha-receptor-2.  This association was true individually for total fiber, insoluble fiber, and soluble fiber.  The researchers found no association with C reactive protein.

Bottom line?  High intake of dietary fiber seems to reduce chronic inflammation, which may, in part, explain the observed clinical benefits of fiber.

Rest assured that the Mediterranean diet is naturally high in fiber.

Steve Parker, M.D.

Reference:  Ma, Yensheng, et al.  Association between dietary fiber and markers of systemic inflammation in the Women’s Health Initiative Observational Study.  Nutrition, 24 (2008): 941-949.

1 Comment

Filed under Fiber

Quote of the Day

MPj04340430000[1]

Good Morning!  This is God.

I will be handling all of your problems today.  I will not need your help.   So relax and have a great day!

 

[I keep a poster of this above my desk.  It’s comforting to re-read it when I start to worry too much.  I hope it does the same for you.]

 -Steve Parker, M.D.

Comments Off on Quote of the Day

Filed under Quote of the Day

Mediterranean Diet + Nuts = Reversal of Metabolic Syndrome

MPj04031620000[1]An article published December 8, 2008, by Bloomberg.com presents results of a recent scientific study in Spain that showed reduction in “metabolic syndrome” by the Mediterranean diet supplemented with nuts.  CBSnews.com, Reuters, and others helped spread the news.  The Bloomberg article was written by Nicole Ostrow.

Metabolic syndrome is a constellation of clinical factors that are associated with increased risk of type 2 diabetes and atherosclerotic complications such as heart attack and stroke.  [Sometimes metabolic sydrome is called Syndrome X, which I sorta like.  Oh, the mystery!]  One in six Americans have the syndrome.  Diagnosis requires at least three of the following five conditions:

  • High blood pressure (130/85 or higher, or using a high blood pressure medication)
  • Low HDL cholesterol:  under 40 mg/dl in a man, under 50 in a women (or either sex taking a cholesterol-lowering drug)
  • Triglycerides over 150 mg/dl (or taking a cholesterol-lowering drug)
  • Abdominal fat:  waist circumference 40 inches or greater in a man, 35 inches or greater in a woman
  • Fasting blood glucose over 100 mg/dl

The scientific study at hand is part of the PREDIMED study being conducted in Spain.  For this portion of the study, 1,224 participants at high risk for cardiovascular disease were randomized to follow a 1) low-fat diet (considered the control group), 2) Mediterranean diet plus 1 liter virgin olive oil per week, or 3) Mediterranean diet plus 30 gm daily of mixed nuts.

Note that the nuts used in this study were walnuts, almonds, and hazelnuts.  Half of all nuts were walnuts; a quarter of the nuts were almonds and a quarter were hazelnuts.

Participants were 55-80 years old, and 61% had metabolic syndrome at baseline.  Participants could eat all they wanted, and there was no increase in physical activity for any of the groups.  Participants were given instructions at baseline and quarterly.

After one year of intervention, the prevalence of metabolic syndrome  was reduced by 14% in the Mediterranean diet plus nuts group compared to the control, low-fat diet group.  The Mediterranean diet plus extra olive oil group reduced prevalence of metabolic syndrome by 7%, but this did not reach statistical significance (P=0.18).

New cases of metabolic syndrome continued to develop at about the same rate in all three groups.  I.e., incident rates were not significantly different.  So, the lower prevalence of metabolic syndrome after one year reflected reversion or clearing of the syndrome in many people who had it at baseline.  Compared to the control group, people in the nutty group were 70% more likely to resolve their metabolic syndrome.  Individuals in the oily group were 30% more likely than controls to resolve the condition.

[Feel free to consult a dictionary for definitions of “prevalence” and “incidence.”]

The researchers conclude that:

A traditional Mediterranean diet enriched with nuts could be a useful tool in the management of the metabolic syndrome. 

My Comments:

Thirty grams (daily) of nuts is a decent-sized snack of about 180 calories.  Thirty grams of almonds formed a heap in the palm of my hand, not touching my fingers.  This is more than the “two tablespoons” reported by CBSnews.com December 9.

If you have metabolic syndrome, you might want to try reversing it with all the usual methods (e.g., lose excess fat weight, exercise more) along with a traditional Mediterranean diet enriched with 30 gm of mixed nuts daily.  As usual, check with your personal healthcare provider first.  Be aware that many of them won’t know about this study.

The puzzling thing to me is:  If the Mediterranean diet plus extra nuts is so effective in reversing metabolic syndrome, why didn’t that study cohort see fewer new cases of metabolic syndrome?

Steve Parker, M.D., author of The Advanced Mediterranean Diet

Additional reference:  Salas-Salvado, Jordi, et al.  Effect of a Mediterranean Diet Supplemented With Nuts on Metabolic Syndrome Status: One-Year Results of the PREDIMED Randomized Trial.  Archives of Internal Medicine, 168 (2008): 2,449-2,458.

4 Comments

Filed under Causes of Diabetes, Mediterranean Diet

TZDs Associated With Broken Bones

You do NOT want this hip bone to break!

You do NOT want this hip bone to break!

A study presented at the 2009 Scientific Sessions of the American Diabetes Association associated thiazolidinedione drugs with a 40% higher fracture risk. 

Thiazolidinediones used in the U.S. are rosiglitazone (Avandia) and pioglitazone (Actos).  “Thiazolidinedione” is so hard to pronounce that my physician colleagues refer to them as “TZDs” or “glitazones.” 

The researchers examined the Medco database – more than 13 million people – looking for people with diabetes between the ages of 43 and 63 at study onset who were using TZDs, metformin, exenatide (Byetta), or a sulfonylurea (e.g., glipizide, glyburide, glimiperide).

Note that this study has not yet undergone the peer-review process and been published in a medical journal.

Take-Home Points 

These results are prelimary and require confirmation and peer-review by experts in the field.  Nevertheless, if I had diabetes and were at risk of broken bones –  presence of osteoporosis, for example – I would ask my doctor about alternatives before taking TZDs.  Stay alert for developments.   

Steve Parker, M.D.

Reference:  Wood, Shelley.  More evidence links glitazones to broken bones.  TheHeart.org, June 12, 2009.

Comments Off on TZDs Associated With Broken Bones

Filed under Drugs for Diabetes

Misleading “Mediterranean Diet” Headline at the Washington Post

Perhaps you read the December 17, 2008, Washington Post (online) article, “Mediterranean-Style Diet Best for Blood Sugar Control.”

The same headline was used by MedlinePlus: Trusted Health Information for You, a service of the U.S. government.  The two articles may be exactly the same.

A physician spokeswoman for the American Heart Association is quoted in the story saying that “…the best diet is a Mediterranean-type diet…”

I mention this only because the Canadian study to which she refers is not a test of the Mediterranean diet in people with diabetes.

[Did you know that some people with diabetes are offended if you call them “diabetics”?  To call them diabetics defines them by their disease.  They’re not diseases, they’re individual humans.]

There are certainly some studies indicating that the traditional Mediterranean diet may be a good one for people with diabetes, and that the Mediterranean diet can prevent type 2 diabetes, but this Canadian study is not one of them.

Steve Parker, M.D.

Reference:  Jenkins, David,  et al.  Effect of a Low-Glycemic Index or High-Cereal Fiber Diet on Type 2 Diabetes: A Randomized Trial.  Journal of the American Medical Association, 300 (2008): 2,742-2,753.

Comments Off on Misleading “Mediterranean Diet” Headline at the Washington Post

Filed under Causes of Diabetes, Mediterranean Diet

Health Benefits of Nuts

You just don't see sickly squirrels.  Hmmm . . .

You just don't see sickly squirrels. Hmmm . . .

I frequently check in at CalorieLab for up-to-date nutrition news.

Karen Collins, M.S., R.D., C.D.N., was a guest contributor there March 14, 2009, writing about the potential health benefits of nuts.  I was aware of the cardiovascular benefits; she taught me about possible salutary effects on cancer and diabetes.

From my own literature review, the cardiac benefits are associated with a nut “dose” of three to five 1-ounce servings a week.

Last December, I blogged about reversal of metabolic syndrome with a Mediterranean Diet supplemented with nuts.

I recommend Ms. Collins’ article to you. 

Steve Parker, M.D.

Reference:  Albert, Christine, et al.  Nut consumption and decreased risk of sudden cardiac death in the Physicians’ Health StudyArchives of Internal Medicine, 162, (2002): 1,382-1,387.

2 Comments

Filed under Health Benefits, Mediterranean Diet

Glycemic Index and Chronic Disease Risk (Mostly in Women)

"Would you like some high-glycemic index bread?"

"Would you like some high-glycemic index bread?"

I recently blogged about glycemic index (GI), glycemic load (GL), and glycemic diets in preparation for today’s post.

The concept of glycemic index was introduced by Jenkins et al in 1981 at the University of Toronto.

Studies investigating the association between disease risk and GI/GL have been inconsistent.  By “inconsistent,” I mean some studies have made an association in one direction or the other, and other studies have not.  Diseases possibly associated with high-glycemic diets have included diabetes, cardiovascular disease, cancer, gallbladder disease, and eye disease.

“Diet” in this post refers to a habitual way of eating, not a weight loss program.

Researchers with the University of Sydney (Sydney, Australia) identified the best-designed published research reports investigating the relationship between certain chronic diseases and glycemic index and load.  The studied diseases were type 2 diabetes, coronary heart disease, stroke, breast cancer, colorectal cancer, pancreatic cancer, endometrial cancer, ovarian cancer, gallbladder disease, and eye disease.

Methodology

Literature databases were searched for articles published between 1981 and March, 2007.  The researchers found 37 studies that enrolled 1,950,198 participants ranging in age from 24 to 76, with BMI’s averaging 23.5 to 29.  These were human prospective cohort studies with a final outcome being occurrence of a chronic disease (not its risk factors).  Twenty-five of the studies were conducted in the U.S., five in Canada, five Europe, and two in Australia.  Ninety percent of participants were women [for reasons not discussed].  Food frequency questionnaires were used in nearly all the studies.  Individual studies generated between 4 to 20 years of follow-up, and 40,129 new cases of target diseases were identified.

Associations between GI, GL, and risk of developing a chronic disease were measured as rate ratios comparing the highest with the lowest quantiles.  For example, GI and GL were measured in the study population.  The population was then divided into four groups (quartiles), reflecting lowest GI/GL to medium to highest GI/GL diets.  The lowest GI/GL quartile was compared with the highest quartile to see if disease occurrence was different between the groups.  Some studies broke the populations into tertiles, quintiles, deciles, etc.

Findings

Comparing the highest with the lowest quantiles, studies with a high GI or GL independently

  • increased the risk of type 2 diabetes by 27 (GL) or 40% (GI)
  • increased the risk of coronary heart disease by 25% (GI)
  • increased the risk of gallbladder disease by 26% (GI) or 41% (GL) [gallstones and biliary colic, I assume, but the authors don’t specify]
  • increased the risk of breast cancer by 8% (GI)
  • increased risk of all studied diseases (11) combined by 14% (GI) or 9% (GL)

Overall, high GI was more strongly associated with chronic disease than was high GL
So low-GI diets may offer greater protection against disease than low-GL diets.

Comments from the Researchers

They speculate that low-GI diets may be more protective than low-GL because the latter can include low-carb foods such as cheese and meat, and low-GI, high-carb foods.  Both eating styles will reduce glucose levels after meals while having very different effects in other areas such as pancreas beta cell function, free fatty acid levels, triglyceride levels, and effects on satiety.

High GI and high GL diets, independently of known confounders, modestly increase the risk of chronic lifestyle-related diseases, with more pronounced effects for type 2 diabetes, coronary heart disease, and gallbladder disease.

Direct quotes:

. . . 90% of participants were female; therefore, the findings may not be generalizable to men.

There are plausible mechanism linking the development of certain chronic diseases with high-GI diets.  Specifically, 2 major pathways have been proposed to explain the association with type 2 diabetes risk.  First the same amount of carbohydrate from high-GI food produces higher blood glucose concentrations and a greater demand for insulin.  The chronically increased insulin demand may eventually result in pancreatic beta cell failure, and, as a consequence, impaired glucose tolerance.  Second, there is evidence that high-GI diets may directly increase insulin resistance through their effect on glycemia, free fatty acids, and counter-regulatory hormone secretion.  High glucose and insulin concentrations are associated with increased risk profiles for cardiovascular disease, including decreased concentrations of HDL cholesterol, increased glycosylated protein, oxidative status, hemostatic variables, and poor endothelial function

Low-GI and/or low-GL diets are independently associated with a reduced risk of certain chronic diseases.  In diabetes and heart disease, the protection is comparable with that seen for whole grain and high fiber intakes.  The findings support the hypothesis that higher postprandial glycemia is a universal mechanism for disease progression.

My Comments

Studies like this tend to accentuate the differences in eating styles since they compare the highest with the lowest post-prandial (after meal) glucose levels.  Most people are closer to the middle of the pack, so a person there has potentially less to gain by moving to a low-GI diet.  But still some to gain, on average, particularly in regards to avoiding type 2 diabetes and coronary heart disease.

[To be fair, many population-based studies use this same quantile technique.  It increases the odds of finding a statistically significant difference.]

Only two of the 37 studies examined coronary heart disease, the cause of heart attacks.  One study was the massive Nurses’ Health Study database with 75,521 women.  The other was the Zutphen (Netherlands) Elderly Study which examined men 64 and older.  Here’s the primary conclusion of the Zutphen authors verbatim:

Our findings do not support the hypothesis that a high-glycemic index diet unfavorably affects metabolic risk factors or increases risk for CHD [coronary heart disease] in elderly men without a history of diabetes or CHD.

So there’s nothing in the meta-analysis at hand to suggest that high-GI/GL diets promote heart disease in males in the general population.

However, the recent Canadian study in Archives of Internal Medicine found strong evidence linking CHD with high-glycemic index diets.  Although not mentioned in the text of that article, Table 3 on page 664 shows that the association is much stonger in women than in men.  Relative risk for women on a high-glycemic index/load diet was 1.5 (95% confidence interval = 1.29-1.71), and for men the relative risk was 1.06 (95% confidence interval = 0.91-1.20).  See reference below.

Nine of the 37 studies examined the occurrence of type 2 diabetes.  Only one of these studied men only – 42,759 men: the abstract is not available online and the Sydney group does not mention if high-GI or high-GL was positively associated with onset of diabetes in this cohort.  Two of the diabetes studies included both men and women, but the abstracts don’t break down the findings by sex.  [I’m trying to deduce if the major overall findings of this meta-analysis apply to men or not.]

I don’t know anybody willing to change their diet just to avoid the risk of gallstones.  It’s only after they develop symptomatic gallstones that they ask me what they can do about them.  The usual answer is surgery.

The report is well-done and seems free of commercial bias, even though several of the researchers are authors or co-authors of popular books on low-GI eating.

Steve Parker, M.D.

References:

Barclay, Alan W.; Petocz, Peter; McMillan-Price, Joanna; Flood, Victoria M.; Prvan, Tania; Mitchell, Paul; and Brand-Miller, Jennie C.  Glycemic index, glycemic load, and chronic disease risk – a meta-analysis of observational studies [of mostly women].  American Journal of Clinical Nutrition, 87 (2008): 627-637.

Brand-Miller, Jennie, et al.  “The New Glucose Revolution: The Authoritative Guide to the Glycemic Index – The Dietary Solution for Lifelong Health.”  Da Capo Press, 2006.

Mente, Andrew, et al.  A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart DiseaseArchives of Internal Medicine, 169 (2009): 659-669.

4 Comments

Filed under Causes of Diabetes, Glycemic Index and Load

Colesevelam (Welchol) Treatment for Type 2 Diabetes

Are you sick and tired of taking pills?

Are you sick and tired of taking pills?

David Mendosa’s May 20, 2009, blog post at HealthCentral.com brought to my attention a little-used diabetes drug, colesevelam HCl.  The brand name is Welchol, and it has been around in the U.S. since 2000 for treatment of high cholesterol.
Colesevelam is in a class called bile acid sequestrants.  Taken in pill form, it is minimally absorbed from the gastrointestinal tract, which generally minimizes the chance for serious side effects.  It can, however, interfere with absorption of many other drugs, thereby impairing the effectiveness of those drugs. 

The U.S. Food and Drug Administration has approved the drug for 1) treating high cholestrol, and 2) treatment of type 2 diabetes in combination with insulin or oral antidiabetes medications.  So, it’s not a diabetic medication to be used by itself.  The most common side effects are constipation and dyspepsia. 

WebMD has a patient-friendly article on colesevelam.

I see very few patients using Welchol for treatment of diabetes, and I’m not entirely sure why.  It may be related to the interference with absorption of other drugs.  Many people with diabetes are on multiple oral medications.  Another reason is that, since it cannot be used alone, it adds a layer of complexity to treatment.  Some physicians would be tempted to use it in a diabetic with high cholesterol: the old “kill two birds with one stone” trick.  However, it’s unknown whether such use acturally reduces cardiovasular disease and mortality.  Statin drugs – the market leaders in lowering cholesterol – do reduce cardiovascular disease rates and mortality. 

By my count, we how have 10 classes of drugs to help us fight diabetes, compared with three or so when I started my medical career.

Steve Parker, M.D.

Additional information:  FDA Prescribing Information.

Comments Off on Colesevelam (Welchol) Treatment for Type 2 Diabetes

Filed under Drugs for Diabetes

Health on the Net Foundation’s Code of Conduct

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

 

I am pleased to announce that in May of this year the Diabetic Mediterranean Diet Blog met the accreditation criteria of the Health on the Net Foundation’s Code of Conduct for medical and health Web sites.

From the HON website:

The Health On the Net Foundation (HON) promotes and guides the deployment of useful and reliable online health information, and its appropriate and efficient use.  Created in 1995, HON is a non-profit, non-governmental organization, accredited to the Economic and Social Council of the United Nations.  For twelve years, HON has focused on the essential question of the provision of health information to citizens, information that respects ethical standards.  To cope with the unprecedented volume of healthcare information available on the Net, the HONcode of conduct offers a multi-stakeholder consensus on standards to protect citizens from misleading health information.

Here are HONcode criteria I pledge to uphold:

  1. Authoritative.  Any medical or health advice provided and hosted on this site will only be given by medically trained and qualified professionals unless a clear statement is made that a piece of advice offered is from a non-medically qualified individual or organisation.
  2. Complementarity.  The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
  3. Privacy.  Confidentiality of data relating to individual patients and visitors to a medical/health Web site, including their identity, is respected by this Web site. The Web site owners undertake to honour or exceed the legal requirements of medical/health information privacy that apply in the country and state where the Web site and mirror sites are located.
  4. Attribution.  Where appropriate, information contained on this site will be supported by clear references to source data and, where possible, have specific HTML links to that data.  The date when a clinical page was last modified will be clearly displayed (e.g. at the bottom of the page).
  5. Justifiability.  Any claims relating to the benefits/performance of a specific treatment, commercial product or service will be supported by appropriate, balanced evidence in the manner outlined above in Principle 4.
  6. Transparency.  The designers of this Web site will seek to provide information in the clearest possible manner and provide contact addresses for visitors that seek further information or support.  The Webmaster will display his/her E-mail address clearly throughout the Web site.
  7. Financial disclosure.  Support for this Web site will be clearly identified, including the identities of commercial and non-commercial organisations that have contributed funding, services or material for the site.
  8. Advertising policy.  If advertising is a source of funding it will be clearly stated.  A brief description of the advertising policy adopted by the Web site owners will be displayed on the site.  Advertising and other promotional material will be presented to viewers in a manner and context that facilitates differentiation between it and the original material created by the institution operating the site.

If you notice any violations of the code, please contact me via email (see Contact page) or contact the Health on the Net Foundation.

Steve Parker, M.D. 

Comments Off on Health on the Net Foundation’s Code of Conduct

Filed under Uncategorized

Spanish Ketogenic Mediterranean Diet

Altea, Plaça de la EsglésiaEver heard of the Spanish Ketogenic Mediterranean Diet?  It looks like a low-carb quasi-Mediterranean diet.

Researchers with the University of Cordoba in Spain studied 40 subjects eating a low-carb “Mediterranean” diet for 12 weeks.  The results were strikingly positive.

Methodology

A medical weight loss clinic was the source of 40 overweight subjects, 22 males and 19 females, average age 38, average body mass index 36.5, average weight 108.6 kg (239 lb).  These folks were interested in losing weight, and were not paid to participate.

Nine subjects were not included in the final analysis due to poor compliance with the study protocol (3), the diet was too expensive (1), a traumatic car wreck (1), or were simply lost to follow-up (4).  So all the data are pooled from the 31 subjects who completed the study.

Blood from all subjects was drawn just before the study began and again after 12 weeks of the diet.

Study diet:  Low-carbohydrate, high in protein [and probably fat, too], unlimited in calories.  Olive oil was the main source of fat (at least 30 ml daily).  Maximum of 30 grams of carbohydrates daily as green vegetables and salad.  200-400 ml daily of red wine.  The authors write:

Participants were permitted 3 portions (200 g/portion) of vegetables daily: 2 portions of salad vegetables (such as alfalfa sprouts, lettuce, escarole, endive, mushrooms, radicchio, radishes, parsley, peppers, chicory, spinach, cucumber, chard and celery), and 1 portion of low-carbohydrate vegetables (such as broccoli, cauliflower, cabbage, artichoke, eggplant, squash, tomato and onion).  3 portions of salad vegetables were allowed only if the portion of low-carbohydrate vegetables were not consumed.  Salad dressing allowed were: garlic, olive oil, vinegar, lemon juice, salt, herbs and spices.

The minimum 30 ml of olive oil were distributed unless in 10 ml per principal meal (breakfast, lunch and dinner).  Red wine (200–400 ml a day) was distributed in 100–200 ml per lunch and dinner.  The protein block was divided in “fish block” and “no fish block”.  The “fish block” included all the types of fish except larger, longer-living predators (swordfish and shark).  The “no fish block” included meat, fowl, eggs, shellfish and cheese.  Both protein blocks were not mixed in the same day and were consumed individually during its day on the condition that at least 4 days of the week were for the “fish block”.

Trans fats (margarines and their derivatives) and processed meats with added sugar were not allowed.

Vitamin and mineral supplements were given.

Subjects measured their ketosis state every morning with urine ketone strips.

Results (averaged)

  • Body weight fell from 108.6 kg (239 lb) to 94.5 kg (209 lb), or 2.5 pounds per week
  • Body mass index fell from 36.5 to 31.8
  • Systolic blood pressure fell from126 to 109 mmHg
  • Diastolic blood pressure fell from 85 to 75 mmHg
  • Total cholesterol fell from 208 to 187 mg/dl
  • LDL chol fell from 115 to 106 mg/dl
  • HDL chol rose from 50 to 55 mg/dl
  • Fasting glucose dropped from 110 to 93 mg/dl
  • Triglycerides fell from 219 to 114 mg/dl
  • No significant differences in male and female subjects
  • No adverse reactions are mentioned

Researchers’ Conclusions

The SKMD [Spanish Ketogenic Mediterranean Diet] is safe, an effective way of losing weight, promoting non-atherogenic lipid profiles, lowering blood pressure and improving fasting blood glucose levels.  Future research should include a larger sample size, a longer term use and a comparison with other ketogenic diets.

My Comments

The researchers called this diet “Mediterranean” based on olive oil, red wine, fish, and vegetables.

What’s “Not Mediterranean” is the paucity of carbohydrates (including whole grains); lack of yogurt, nuts, and legumes; and the high meat/protein intake.

The emphasis on olive oil, red wine, and fish could make this healthier than other ketogenic diets.

Ketogenic diets are notorious for high drop-out rates compared to other diets.  Most people can follow a ketogenic diet for only two or three months.  But several studies suggest greater short-term weight loss for people who stick with it.  Efficacy and superiority are little different from other diets as measured at one year out.

Many of the metabolic improvements seen here might be duplicated with loss of 30 pounds (13.6 kg) over 12 weeks using any reasonable diet.

Average fasting blood sugars in these subjects was 109 mg/dl.  Although not mentioned by the authors, this is in the prediabetes range.  The diet reduced average fasting blood sugar to 93, which would mean resolution of prediabetes.  Dropping body mass index from 36 to 32 by any method would tend to cure prediabetes.

Elevated blood sugar is one component of the “metabolic syndrome.”  Metabolic syndrome was recently shown to be reversible with a Mediterranean diet supplemented with nuts.

I suspect this would be a good program for an overweight person with uncontrolled type 2 diabetes, too.  But it has never been studied in a diabetic population.  So, who knows for sure?

If you’re thinking about doing something like this, get more information and be sure to get your doctor’s approval first.

Steve Parker, M.D.

Addendum:

On April 6, 2008, I had a delightful conversation with Jimmy Moore, of Livin’ La Vida Low-Carb fame regarding this study.  It struck me that the Spanish Ketogenic Mediterranean Diet is probably higher in protein and lower in fat than many other ketogenic weight-loss diets.  Since fish is emphasized over other animal-derived foods, it’s likely also lower in saturated fat.  [In low-carb diets, carbohydrates are substituted with either fats or proteins.]  I’m also convinced I will eventually have to review the validity of the dogmatic diet-heart hypothesis:  Dietary saturated fat, total fat, and cholesterol contribute to atherosclerosis and associated premature death from heart attacks and strokes.

References and Additional Reading:

Perez-Guisado, J., Munoz-Serrano, A., and Alonso-Moraga, A.  Spanish Ketogenic Mediterranean diet: a healthy cardiovascular diet for weight lossNutrition Journal, 2008, 7:30.   doi:10.1186/1475-2891-7-30

Bravata, D.M., et al.  Efficacy and safety of low-carbohydrate diets: a systematic reviewJournal of the American Medical Association, 289 (2003): 1,837-1,850.

Gardner, C.D., et al.  Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trialJournal of the American Medical Association, 297 (2007): 696-677.

Stern, L., et al.  The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trialAnnals of Internal Medicine, 140 (2004): 778-785.

Shai, Iris, et al.  Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat DietNew England Journal of Medicine, 359 (2008): 229-241.

11 Comments

Filed under Carbohydrate, ketogenic diet, Weight Loss